DAFNA Capital Management
Latest statistics and disclosures from DAFNA Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are XBI, STXS, CYTK, IDYA, MRUS, and represent 32.14% of DAFNA Capital Management's stock portfolio.
- Added to shares of these 10 stocks: ATRC, CATX, PODD, LRMR, KALV, AQST, LCTX, STOK, ALEC, BNTX.
- Started 10 new stock positions in BNTX, Alto Neuroscience, CATX, PODD, STOK, ACET, LCTX, APRE, PYPD, AQST.
- Reduced shares in these 10 stocks: Karuna Therapeutics Ord (-$15M), , SAGE (-$5.3M), Mirati Therapeutics (-$5.3M), XBI (-$5.0M), ASND, VKTX, MRUS, ATXS, IDYA.
- Sold out of its positions in AMLX, ARGX, CGEM, ELEV, ImmunoGen, Karuna Therapeutics Ord, KNTE, MGNX, MREO, Mirati Therapeutics. ORIC, SAGE, SPRB, VTGN.
- DAFNA Capital Management was a net seller of stock by $-48M.
- DAFNA Capital Management has $439M in assets under management (AUM), dropping by 5.26%.
- Central Index Key (CIK): 0001389933
Tip: Access up to 7 years of quarterly data
Positions held by DAFNA Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for DAFNA Capital Management
DAFNA Capital Management holds 72 positions in its portfolio as reported in the March 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Spdr S&p Biotech Etf Etf (XBI) | 9.3 | $41M | -10% | 431k | 94.89 |
|
| Stereotaxis Com New (STXS) | 8.1 | $36M | 14M | 2.61 |
|
|
| Cytokinetics Com New (CYTK) | 6.4 | $28M | 398k | 70.11 |
|
|
| Ideaya Biosciences (IDYA) | 4.5 | $20M | -13% | 446k | 43.88 |
|
| Merus N V (MRUS) | 3.9 | $17M | -16% | 379k | 45.03 |
|
| Revolution Medicines (RVMD) | 3.8 | $17M | 512k | 32.23 |
|
|
| Viking Therapeutics (VKTX) | 3.6 | $16M | -21% | 194k | 82.00 |
|
| Syndax Pharmaceuticals (SNDX) | 3.6 | $16M | -11% | 660k | 23.80 |
|
| Ishares Nasdaq Biotech Indx Etf (IBB) | 3.2 | $14M | 103k | 137.22 |
|
|
| Ascendis Pharma A/s Sponsored Adr (ASND) | 3.2 | $14M | -25% | 93k | 151.17 |
|
| Xenon Pharmaceuticals (XENE) | 2.7 | $12M | 274k | 43.05 |
|
|
| Day One Biopharmaceuticals I (DAWN) | 2.5 | $11M | -2% | 667k | 16.52 |
|
| Blueprint Medicines (BPMC) | 2.3 | $10M | -3% | 107k | 94.86 |
|
| Neurocrine Biosciences (NBIX) | 2.2 | $9.9M | 72k | 137.92 |
|
|
| Kalvista Pharmaceuticals (KALV) | 2.2 | $9.6M | +34% | 807k | 11.86 |
|
| Tandem Diabetes Care Com New (TNDM) | 2.1 | $9.1M | +16% | 258k | 35.41 |
|
| Dex (DXCM) | 2.1 | $9.1M | -2% | 66k | 138.70 |
|
| Kura Oncology (KURA) | 2.0 | $8.8M | -16% | 413k | 21.33 |
|
| AtriCure (ATRC) | 1.9 | $8.2M | +115% | 271k | 30.42 |
|
| Morphic Hldg (MORF) | 1.9 | $8.2M | 232k | 35.20 |
|
|
| Axogen (AXGN) | 1.7 | $7.6M | 936k | 8.07 |
|
|
| Biohaven (BHVN) | 1.5 | $6.5M | -29% | 119k | 54.69 |
|
| 2seventy Bio Common Stock (TSVT) | 1.5 | $6.4M | -16% | 1.2M | 5.35 |
|
| Edgewise Therapeutics (EWTX) | 1.3 | $5.6M | -31% | 306k | 18.24 |
|
| Alector (ALEC) | 1.3 | $5.5M | +49% | 913k | 6.02 |
|
| Century Therapeutics (IPSC) | 1.2 | $5.5M | 1.3M | 4.18 |
|
|
| Larimar Therapeutics (LRMR) | 1.1 | $5.0M | +102% | 656k | 7.59 |
|
| Ascendis Pharma A/s Note 2.250% 4/0 (Principal) | 1.0 | $4.6M | 4.0M | 1.15 |
|
|
| Keros Therapeutics (KROS) | 1.0 | $4.5M | -8% | 68k | 66.20 |
|
| Arcus Biosciences Incorporated (RCUS) | 1.0 | $4.4M | 232k | 18.88 |
|
|
| Galapagos Nv Spon Adr (GLPG) | 1.0 | $4.2M | 130k | 32.20 |
|
|
| IsoRay (CATX) | 0.8 | $3.7M | NEW | 3.1M | 1.19 |
|
| BioCryst Pharmaceuticals (BCRX) | 0.8 | $3.6M | 710k | 5.08 |
|
|
| Astria Therapeutics (ATXS) | 0.7 | $3.1M | -50% | 223k | 14.07 |
|
| Regulus Therapeutics (RGLS) | 0.7 | $3.1M | -3% | 1.1M | 2.88 |
|
| Bicycle Therapeutics Sponsored Ads (BCYC) | 0.7 | $3.0M | 122k | 24.90 |
|
|
| Accuray Incorporated (ARAY) | 0.7 | $3.0M | 1.2M | 2.47 |
|
|
| Insulet Corporation (PODD) | 0.6 | $2.7M | NEW | 16k | 171.40 |
|
| Procept Biorobotics Corp (PRCT) | 0.6 | $2.7M | -13% | 55k | 49.42 |
|
| Mediwound Shs New (MDWD) | 0.6 | $2.7M | -26% | 189k | 14.25 |
|
| Silverback Therapeutics (SPRY) | 0.6 | $2.4M | -23% | 239k | 10.22 |
|
| Aquestive Therapeutics (AQST) | 0.5 | $2.1M | NEW | 500k | 4.26 |
|
| Proqr Therapeutics N V Shs Euro (PRQR) | 0.5 | $2.1M | -3% | 906k | 2.29 |
|
| Compass Pathways Sponsored Ads (CMPS) | 0.5 | $2.0M | +26% | 243k | 8.32 |
|
| Lineage Cell Therapeutics In (LCTX) | 0.5 | $2.0M | NEW | 1.4M | 1.48 |
|
| Stoke Therapeutics (STOK) | 0.4 | $2.0M | NEW | 145k | 13.50 |
|
| Sutro Biopharma (STRO) | 0.4 | $1.9M | +18% | 334k | 5.65 |
|
| Inogen (INGN) | 0.4 | $1.7M | +1291% | 209k | 8.07 |
|
| Gossamer Bio (GOSS) | 0.4 | $1.7M | -4% | 1.4M | 1.18 |
|
| Brainsway Sponsored Ads (BWAY) | 0.4 | $1.6M | -3% | 298k | 5.29 |
|
| Biontech Se Sponsored Ads (BNTX) | 0.4 | $1.6M | NEW | 17k | 92.25 |
|
| Immatics Nv SHS (IMTX) | 0.3 | $1.5M | +38% | 145k | 10.51 |
|
| Neuronetics (STIM) | 0.3 | $1.5M | 314k | 4.76 |
|
|
| Adicet Bio (ACET) | 0.3 | $1.4M | NEW | 600k | 2.35 |
|
| Autolus Therapeutics Spon Ads (AUTL) | 0.3 | $1.4M | +13% | 217k | 6.38 |
|
| Acelyrin (SLRN) | 0.3 | $1.4M | -45% | 203k | 6.75 |
|
| Iteos Therapeutics (ITOS) | 0.3 | $1.3M | 99k | 13.64 |
|
|
| Mineralys Therapeutics (MLYS) | 0.3 | $1.2M | +492% | 90k | 12.91 |
|
| Compugen Ord (CGEN) | 0.3 | $1.1M | +109% | 430k | 2.58 |
|
| Immunovant (IMVT) | 0.2 | $950k | -27% | 29k | 32.31 |
|
| Acrivon Therapeutics Common Stock (ACRV) | 0.2 | $939k | 131k | 7.15 |
|
|
| Aprea Therapeutics Com New (APRE) | 0.2 | $918k | NEW | 137k | 6.69 |
|
| Polypid (PYPD) | 0.2 | $853k | NEW | 185k | 4.60 |
|
| Syros Pharmaceuticals Com New (SYRS) | 0.2 | $727k | -36% | 136k | 5.35 |
|
| Adaptimmune Therapeutics Sponds Adr (ADAP) | 0.1 | $539k | -2% | 341k | 1.58 |
|
| Masimo Corporation (MASI) | 0.1 | $441k | 3.0k | 146.85 |
|
|
| Nevro (NVRO) | 0.1 | $404k | 28k | 14.44 |
|
|
| Karyopharm Therapeutics (KPTI) | 0.1 | $291k | 193k | 1.51 |
|
|
| Vigil Neuroscience (VIGL) | 0.1 | $245k | 72k | 3.41 |
|
|
| Compass Therapeutics (CMPX) | 0.1 | $231k | 117k | 1.98 |
|
|
| Spero Therapeutics (SPRO) | 0.0 | $215k | 125k | 1.72 |
|
|
| Alto Neuroscience Com Shs | 0.0 | $154k | NEW | 10k | 15.35 |
|
Past Filings by DAFNA Capital Management
SEC 13F filings are viewable for DAFNA Capital Management going back to 2010
- DAFNA Capital Management 2024 Q1 filed May 15, 2024
- DAFNA Capital Management 2023 Q4 filed Feb. 14, 2024
- DAFNA Capital Management 2023 Q3 filed Nov. 14, 2023
- DAFNA Capital Management 2023 Q2 filed Aug. 14, 2023
- DAFNA Capital Management 2023 Q1 filed May 15, 2023
- DAFNA Capital Management 2022 Q4 filed Feb. 14, 2023
- DAFNA Capital Management 2022 Q3 filed Nov. 14, 2022
- DAFNA Capital Management 2022 Q2 filed Aug. 15, 2022
- DAFNA Capital Management 2022 Q1 filed May 16, 2022
- DAFNA Capital Management 2021 Q4 filed Feb. 14, 2022
- DAFNA Capital Management 2021 Q3 filed Nov. 15, 2021
- DAFNA Capital Management 2021 Q2 filed Aug. 16, 2021
- DAFNA Capital Management 2021 Q1 filed May 17, 2021
- DAFNA Capital Management 2020 Q4 filed Feb. 16, 2021
- DAFNA Capital Management 2020 Q3 filed Nov. 16, 2020
- DAFNA Capital Management 2020 Q2 filed Aug. 14, 2020